Cargando…

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BACKGROUND: The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase toxicities in patients undergoing chemoradiati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoder, Alison K., Lakomy, David S., Dong, Yongquan, Raychaudhury, Suchismita, Royse, Kathryn, Hartman, Christine, Richardson, Peter, White, Donna L., Kramer, Jennifer R., Lin, Lilie L., Chiao, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256603/ https://www.ncbi.nlm.nih.gov/pubmed/34225709 http://dx.doi.org/10.1186/s12885-021-08514-z

Ejemplares similares

Incidence and survival for oropharynx and non‐oropharynx head and neck cancers among veterans living with HIV
por: Mazul, Angela L., et al.
Publicado: (2020)

Effect of Body Weight and Other Metabolic Factors on Risk of Non-Small Cell Lung Cancer among Veterans with HIV and a History of Smoking
por: Garcia, Jose M., et al.
Publicado: (2020)

SAT-093 Effect of HIV Infection and Antiretroviral Therapy Use on Body Weight and Body Weight Changes over a 5-Year Period in US Veterans
por: Garcia, Jose, et al.
Publicado: (2019)

Area deprivation index and segregation on the risk of HIV: a U.S. Veteran case–control study
por: Oluyomi, Abiodun O., et al.
Publicado: (2023)

Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer
por: Vogel, Jennifer, et al.
Publicado: (2020)

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer
por: Savoie, Marissa B., et al.
Publicado: (2019)

Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A population-based study
por: Wu, Yinhang, et al.
Publicado: (2020)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans
por: Mbang, Pamela A., et al.
Publicado: (2015)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma
por: Provencher, Sawyna, et al.
Publicado: (2010)

Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer
por: Voong, Khinh Ranh, et al.
Publicado: (2020)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
por: Dewas, Claire Vautravers, et al.
Publicado: (2012)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review
por: Lakomy, David S., et al.
Publicado: (2021)

Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer
por: Gaber, Charles E, et al.
Publicado: (2022)

Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review
por: Rahimy, Elham, et al.
Publicado: (2020)

Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer
por: Matoska, Thomas, et al.
Publicado: (2023)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study
por: Chu, William, et al.
Publicado: (2023)

Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
por: Shi, Feiya, et al.
Publicado: (2022)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum
por: Long, David E., et al.
Publicado: (2020)

Definitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
por: Anthony, Michelle, et al.
Publicado: (2020)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Factors predictive of parametrial boost in patients with cervical cancer treated with definitive chemoradiation
por: Jamora, Kurl E., et al.
Publicado: (2022)

Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
por: Albana, Jasen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gofmfkbshnf2nt9udkrsg5bgq9